Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.

Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an antiviral agent and an antidepressant as an active ingredient and to which a biguanide-based compound can be added, and more specifically, efavirenz, etravirine, rilpivirine, lopinavir, atazanavir, darunavir, and ritonavir as an antiviral agent, and fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, amitriptyline, clomipramine, nortriptyline, desipramine, amoxapine, maprotilline, trimipramine, protriptyline, and melithracene as an antidepressant, in complex, mixture, or combination administration, or efavirenz and fluoxetine with metformin, a biguanide compound, in complex, mixture, or combination administration, shows the significant synergistic anti-cancer activity than when each was administered alone, and so, finally the antiviral agent and antidepressant according to the present invention can be effectively used as an active ingredient in a composition for preventing or treating cancer.

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an antiviral agent and an antidepressant as an active ingredient and to which a biguanide-based compound can be added, and more specifically, efavirenz, etravirine, rilpivirine, lopinavir, atazanavir, darunavir, and ritonavir as an antiviral agent, and fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, amitriptyline, clomipramine, nortriptyline, desipramine, amoxapine, maprotilline, trimipramine, protriptyline, and melithracene as an antidepressant, in complex, mixture, or combination administration, or efavirenz and fluoxetine with metformin, a biguanide compound, in complex, mixture, or combination administration, shows the significant synergistic anti-cancer activity than when each was administered alone, and so, finally the antiviral agent and antidepressant according to the present invention can be effectively used as an active ingredient in a composition for preventing or treating cancer.

Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.

Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.